IL148192A0 - Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure - Google Patents

Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure

Info

Publication number
IL148192A0
IL148192A0 IL14819200A IL14819200A IL148192A0 IL 148192 A0 IL148192 A0 IL 148192A0 IL 14819200 A IL14819200 A IL 14819200A IL 14819200 A IL14819200 A IL 14819200A IL 148192 A0 IL148192 A0 IL 148192A0
Authority
IL
Israel
Prior art keywords
crystals
coordinates
binding domain
crystal structure
ligand binding
Prior art date
Application number
IL14819200A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL148192A0 publication Critical patent/IL148192A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
IL14819200A 1999-10-14 2000-10-13 Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure IL148192A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15939499P 1999-10-14 1999-10-14
PCT/US2000/028495 WO2001027622A1 (fr) 1999-10-14 2000-10-13 Structure cristallographique du domaine de liaison du ligand du recepteur androgene

Publications (1)

Publication Number Publication Date
IL148192A0 true IL148192A0 (en) 2002-09-12

Family

ID=22572436

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14819200A IL148192A0 (en) 1999-10-14 2000-10-13 Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure

Country Status (7)

Country Link
US (2) US6795776B1 (fr)
EP (1) EP1222459A4 (fr)
JP (1) JP2003511467A (fr)
AU (1) AU775928B2 (fr)
CA (1) CA2388253A1 (fr)
IL (1) IL148192A0 (fr)
WO (1) WO2001027622A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
EP1402451A4 (fr) * 2001-06-07 2005-01-05 Wyeth Corp Structure de solution d'il-13 et utilisation de celle-ci
EP1399475A2 (fr) * 2001-06-07 2004-03-24 F. Hoffmann-La Roche Ag Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
JP4605557B2 (ja) 2001-12-06 2011-01-05 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療
MXPA04007639A (es) 2002-02-07 2005-07-13 Gtx Inc Tratamiento de hiperplasia benigna de la prostata con un modulador de receptor de androgeno selectivo (sarm).
ES2528764T3 (es) 2002-02-28 2015-02-12 University Of Tennessee Research Foundation Moduladores selectivos multisustituidos del receptor de andrógeno y métodos de uso de los mismos
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
GEP20074191B (en) 2002-06-17 2007-09-10 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2004052302A2 (fr) * 2002-12-10 2004-06-24 The Regents Of The University Of California Procede pour creer des produits pharmaceutiques a recepteurs nucleaires specifiques de haute affinite
CA2564584A1 (fr) * 2004-04-22 2005-12-01 Carsten Schubert Complexes inhibiteurs hdm2 et utilisations de ceux-ci
US20060069019A1 (en) * 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2008024456A2 (fr) 2006-08-24 2008-02-28 University Of Tennessee Research Foundation Acylanilides substitués et procédés d'utilisation de ceux-ci
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2010000066A1 (fr) * 2008-07-02 2010-01-07 British Columbia Cancer Agency Branch Produits thérapeutiques dérivés d'éthers diglycidiques et leurs procédés d'utilisation
CA2786319C (fr) 2010-01-06 2019-03-12 British Columbia Cancer Agency Branch Derives du bisphenol et leur utilisation en tant que modulateurs de l'activite du recepteur des androgenes
WO2012139039A2 (fr) * 2011-04-08 2012-10-11 British Columbia Cancer Agency Branch Composés de bisphénol et leurs procédés d'utilisation
WO2013067131A1 (fr) * 2011-11-02 2013-05-10 Medivation Technologies, Inc. Méthodes de traitement
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
EP3733170A1 (fr) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Procédé de traitement de cancers du sein positifs aux récepteurs des androgène (ar) à l'aide d'un modulateur sélectif des récepteurs androgènes (sarm)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PE20160091A1 (es) 2013-05-10 2016-03-03 British Columbia Cancer Agency Branch Derivados de ester de moduladores del receptor de androgeno y metodos para su uso
JP2016530285A (ja) 2013-09-09 2016-09-29 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
HUE057962T2 (hu) 2015-01-13 2022-06-28 British Columbia Cancer Agency Branch Heterociklusos vegyületek rák képalkotására és kezelésére és eljárás ezek alkalamzására
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (fr) 2018-05-25 2019-11-28 Essa Pharma, Inc. Modulateurs du récepteur des androgènes et leurs procédés d'utilisation
CA3115101A1 (fr) 2018-10-18 2020-04-23 Essa Pharma, Inc. Modulateurs du recepteur des androgenes et leurs methodes d'utilisation
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
JP2708456B2 (ja) 1988-03-31 1998-02-04 武田薬品工業株式会社 自動合成装置
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688810A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5854202A (en) * 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
DE69636677D1 (de) * 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP0980386A2 (fr) 1997-06-10 2000-02-23 Karo Bio Ab Ligands se liant aux recepteurs d'oestrogenes
KR20010042373A (ko) 1998-03-30 2001-05-25 린다 에스. 스티븐슨 핵 수용체 활성을 조절하는 방법 및 화합물

Also Published As

Publication number Publication date
EP1222459A4 (fr) 2003-01-22
WO2001027622A1 (fr) 2001-04-19
CA2388253A1 (fr) 2001-04-19
US7225083B2 (en) 2007-05-29
EP1222459A1 (fr) 2002-07-17
US20040243316A1 (en) 2004-12-02
AU1087001A (en) 2001-04-23
US6795776B1 (en) 2004-09-21
JP2003511467A (ja) 2003-03-25
AU775928B2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
IL148192A0 (en) Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure
IL148046A0 (en) Bicyclic androgen and progesterone receptor modulator compounds and methods
HUP0200554A2 (en) Crystal structure of cpla2 and methods of identifying agosists and antagonists using same
HK1050674A1 (en) Naphthalene derivative and liquid crystal composition comprising the same
IL154272A0 (en) The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
HUP0200429A2 (en) Soluble receptor br43x2 and methods of using
EP1420796A4 (fr) Modulateurs du recepteur des androgenes et leurs procedes d'utilisation
HK1043788A1 (zh) 四環黃體酮受體調節劑化合物及方法
GB9811477D0 (en) Liquid crystal device
HUP0001748A3 (en) Transdermal device for the delivery of testosterone
GB9906168D0 (en) Liquid crystal compounds
TW411838U (en) Fastening hook for spine and reposition device for fastening spine
GB9922792D0 (en) Liquid crystal device and display
GB2350225B (en) Liquid crystal display device and method of manufacturing the same
AU2003298654A8 (en) Structure of the farnesoid x receptor ligand binding domain and methods of use therefor
TW539158U (en) Pivoting structure and liquid crystal display using the same
DE69928024D1 (de) Flüssigkristallschirm
GB9911246D0 (en) Reflective liquid crystal devices
AU7087000A (en) Crystal structures of domains of receptor protein tyrosine kinases and their ligands
GB0023793D0 (en) Liquid crystal display device and fabrication method of the same
AU5649099A (en) Compound having tetrahydronaphthalene skeleton and liquid crystal composition containing the same
AU2189501A (en) Use of isoquinoline and quinoline containing substances as imidazoline receptor ligands
TW496320U (en) Retracting and aligning structure for concealed liquid crystal screen
HK1030264A1 (en) Liquid crystal display element and liquid crystal display apparatus using the same
GB9807196D0 (en) Liquid crystal device